We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen neglected to provide Genentech with information on its manufacturing process for an Avastin biosimilar, violating statutory requirements, Genentech contends in a complaint. Read More
New Jersey federal judges validated patents on Sunovion Pharmaceuticals’ schizophrenia drug Latuda and Helsinn’s nausea therapy Aloxi, dealing a blow to sponsors looking to launch generic versions of the drugs. Read More
Celgene will pay $198.5 million to settle a case alleging the company failed to pay royalties on patents covering the multiple myeloma drugs Revlimid and Pomalyst/Imnovid. Read More
Aspen Pharma and Deco Pharma, the company’s distributor, face disciplinary proceedings from Spain’s antitrust authority for allegedly limiting the distribution and hiking the prices of drugs. Read More
British Prime Minister Theresa May wants to strike a deal with the UK’s life sciences industry to increase the sector’s productivity and maximize the country’s investment in research and development. Read More
Sandoz is arguing the Federal Circuit misinterpreted federal law when ruling that biosimilar makers must wait six months after an FDA approval to launch a product. Read More
In a loss for Shire, a three-judge panel for the U.S. Court of Appeals for the Federal Circuit ruled Actavis did not infringe a patent covering the ulcerative colitis drug Lialda, reversing a lower court decision. Read More